BIOCON - IntraDay Trade Analysis with Live Signals
Back to ListIntraDay Trade Rating: 3.3
| Stock Code | BIOCON | Market Cap | 67,106 Cr. | Current Price | 414 ₹ | High / Low | 440 ₹ |
| Stock P/E | 281 | Book Value | 167 ₹ | Dividend Yield | 0.12 % | ROCE | 1.92 % |
| ROE | 1.24 % | Face Value | 5.00 ₹ | DMA 50 | 402 ₹ | DMA 200 | 382 ₹ |
| Chg in FII Hold | 0.13 % | Chg in DII Hold | 2.34 % | PAT Qtr | 67.3 Cr. | PAT Prev Qtr | 111 Cr. |
| RSI | 52.3 | MACD | 3.73 | Volume | 16,90,923 | Avg Vol 1Wk | 22,65,894 |
| Low price | 331 ₹ | High price | 440 ₹ | PEG Ratio | 1.65 | Debt to equity | 0.04 |
| 52w Index | 75.7 % | Qtr Profit Var | 218 % | EPS | 0.23 ₹ | Industry PE | 32.1 |
📊 Analysis:
BIOCON shows weak-to-moderate potential for intraday trading today. RSI at 52.3 indicates neutral momentum, while MACD at 3.73 suggests mild bullishness. Current price (414 ₹) trades above both 50 DMA (402 ₹) and 200 DMA (382 ₹), reflecting short-term strength. However, volume (16,90,923) is below the weekly average (22,65,894), reducing conviction.
Optimal buy zone: 410–415 ₹.
Profit-taking levels: 422–428 ₹.
Stop-loss: 405 ₹.
If already holding, exit intraday if price fails to sustain above 410 ₹ or RSI dips below 50 with declining volume. Consider partial profit booking if price sustains above 422 ₹ with strong momentum.
---
✅ Positive
- DII holdings increased (+2.34%), showing strong domestic institutional support.
- FII holdings also improved (+0.13%), reflecting foreign investor confidence.
- PEG ratio (1.65) indicates reasonable growth valuation.
- Debt-to-equity ratio at 0.04 ensures balance sheet strength.
⚠️ Limitation
- Extremely high P/E (281) vs industry (32.1) indicates severe overvaluation.
- Weak ROCE (1.92%) and ROE (1.24%) highlight poor efficiency.
- EPS at 0.23 ₹ remains very low relative to valuation.
- Volume below average reduces breakout conviction.
📉 Company Negative News
- Sequential PAT decline (111 Cr. → 67.3 Cr.) raises sustainability concerns.
- Valuation concerns due to high P/E and poor returns on capital.
📈 Company Positive News
- Quarterly profit growth of 218% YoY adds strong momentum.
- Institutional inflows (FII +0.13%, DII +2.34%) reflect investor confidence.
🏭 Industry
- Biopharma sector benefits from global demand for generics and biosimilars.
- Industry PE (32.1) far below BIOCON’s valuation, highlighting premium pricing.
🔎 Conclusion
⚖️ BIOCON is a weak-to-moderate intraday candidate today due to poor fundamentals and stretched valuations. Buy near 410–415 ₹, target 422–428 ₹, and maintain a strict stop-loss at 405 ₹. Exit intraday if price action weakens below 410 ₹ or RSI fails to hold above 50 with low volume. Risk-managed execution is critical given weak efficiency metrics and high valuation multiples.
Would you like me to extend this into a biopharma intraday overlay comparing Biocon, Sun Pharma, and Dr. Reddy’s for sharper benchmarking?